Redhill Biopharma Ltd.
9 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 2 name spellings.
9
Ending by 2030
Feb 2029
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jan 7, 2027The maintenance fee for Methods and Compositions for Treating Inflammatory Bowel Disease (US 9,072,763) comes due Jan 7, 2027. Unpaid by Jul 7, 2027, it lapses early.
- 2 fees due Apr 8 to 17, 2027 · next Apr 8
- 1 fee due May 5, 2027The maintenance fee for Combination Therapies for Treating Cancer (US 10,463,654) comes due May 5, 2027. Unpaid by Nov 5, 2027, it lapses early.
- 1 fee due Jun 1, 2027The maintenance fee for Methods and Compositions Comprising Rifabutin, Clarithromycin, and Clofazimine (US 9,198,926) comes due Jun 1, 2027. Unpaid by Dec 1, 2027, it lapses early.
- 1 fee due Jul 28, 2027The maintenance fee for Therapy for Inhibition of Single-Stranded RNA Virus Replication (US 10,543,222) comes due Jul 28, 2027. Unpaid by Jan 28, 2028, it lapses early.
- 1 fee due Sep 5, 2027The maintenance fee for Serine Protease Inhibitor for Treating Coronavirus Infection (US 11,918,560) comes due Sep 5, 2027. Unpaid by Mar 6, 2028, it lapses early.
- 1 fee due Oct 19, 2027The maintenance fee for Compositions Comprising Rifabutin, Clarithromycin, and Clofazimine and Uses Thereof (US 9,314,477) comes due Oct 19, 2027. Unpaid by Apr 19, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,343,511 | Methods and Compositions for Treating Inflammatory Bowel Disease In force · High confidence | In force | High confidence | |
| US 9,198,926 | Methods and Compositions Comprising Rifabutin, Clarithromycin, and Clofazimine In force · Medium confidence | In force | Medium confidence | |
| US 9,314,477 | Compositions Comprising Rifabutin, Clarithromycin, and Clofazimine and Uses Thereof In force · Medium confidence | In force | Medium confidence | |
| US 10,105,379 | Pharmaceutical Compositions Comprising Three Antibiotics In force · Medium confidence | In force | Medium confidence | |
| US 10,143,702 | Fixed-Dose Pharmaceutical Composition Comprising Rifabutin, Clarithromycin, and Clofazimine In force · Medium confidence | In force | Medium confidence | |
| US 10,434,114 | Methods of Treating a Bacterial Infection Using a Fixed-Dose Pharmaceutical Composition Comprising Three Antibiotics In force · Medium confidence | In force | Medium confidence | |
| US 10,765,691 | Method for Treating Crohn's Disease Using Triple Antimicrobial All-In-One Formulation In force · High confidence | In force | High confidence | |
| US 11,090,326 | Fixed-Dose Pharmaceutical Composition Comprising Rifabutin, Clarithromycin, and Clofazimine In force · High confidence | In force | High confidence | |
| US 9,072,763 | Methods and Compositions for Treating Inflammatory Bowel Disease In force · High confidence | In force | High confidence | |
| US 9,901,638 | Composition and Method for Treating an Autoimmune Disease In force · High confidence | In force | High confidence |
Also on record, not counted in the 34: 9 patents in force now held by others · 1 lapsed for an unpaid fee · 6 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
1 pending · 8 abandoned